Enrollment Temporarily Closed
This study is temporarily closed to new enrollments. Please contact the study team for more information or check back frequently.

Merck-U02-Substudy 02C_Neoadjuvant_Melanoma - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if different combinations of experimental drugs are safe and effective treatments to give people before and after surgery to remove melanoma.

What is the Condition Being Studied?


Who Can Participate in the Study?

Adults ages 18+ who:
- Are diagnosed with stages IIIB, IIIC, or IIID melanoma
- Have melanoma that can be treated with surgery

For more information about who can be in this study, please contact the study team at ivy.belskie@duke.edu.

Age Group

What is Involved?

The study is divided into two periods: a screening period and a study dosing period.

If you choose to join this study, during the screening period you will:
- Have physical exams
- Have blood draws
- Have other tests done to assess your eligibility

If you are found to be eligible, you will continue on to the study dosing period. During this period, you will:
- Be randomly assigned (by chance, like taking numbers from a hat) to 1 of 3 groups
-- Group 1 will be treated with pembrolizumab and MK-7684 before surgery, and then pembrolizumab alone after surgery
-- Group 2 will be treated with pembrolizumab and V937 before surgery, and then pembrolizumab alone after surgery
-- Group 2 will be treated with only pembrolizumab before and after surgery

Study Details

Full Title
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00107692
NCT: NCT04303169
Phase I/II
Enrollment Status
Enrollment Temporarily Closed
Contact the Duke Recruitment Innovation Center